Comparative Pharmacology
Head-to-head clinical analysis: PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN versus ROXICET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN versus ROXICET.
PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN vs ROXICET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propoxyphene is a mu-opioid receptor agonist; acetaminophen inhibits cyclooxygenase (COX) and modulates central pain pathways.
Roxicet is a combination of oxycodone, a full mu-opioid receptor agonist, and acetaminophen, which inhibits cyclooxygenase (COX) enzymes, primarily in the central nervous system, to reduce pain perception and fever.
One tablet (propoxyphene HCl 65 mg/acetaminophen 650 mg) orally every 4 hours as needed for pain; maximum: 6 tablets per day.
1-2 tablets (oxycodone 5-10 mg/acetaminophen 325-650 mg) orally every 4-6 hours as needed for pain; maximum acetaminophen 4000 mg/day (3000 mg/day in high-risk patients).
None Documented
None Documented
Propoxyphene: 6-12 h (prolonged in hepatic disease); Norpropoxyphene (active metabolite): 30-36 h (accumulation risk). Acetaminophen: 2-3 h (prolonged in hepatic disease).
Oxycodone: 3-5 hours (immediate-release); prolonged in hepatic/renal impairment. Acetaminophen: 2-3 hours.
Renal: Propoxyphene ~20-25% as unchanged drug and metabolites; Acetaminophen ~85-90% as glucuronide and sulfate conjugates, <5% unchanged. Fecal: Minimal for both.
Primarily renal (90% as glucuronide conjugates, <10% unchanged). Biliary/fecal excretion is minor (<5%).
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination